There are now four FDA approvals that have molecular-specific licenses for lung cancer, these include ALK rearrangements, EGFR mutations, BRAF V600E mutations and ROS1 rearrangements. Now, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the abnormalities that do not have FDA-approved targted drugs and raises the interesting question of who is actually benefitting from the treatment options.
More focus is needed on subtypes of lung cancer that do not have FDA-approved targeted therapies
